Clinical studies of lactobacilli showing immunomodulatory activity in various pathologies
| Bacteria | Dose | Pathology | Ref. (Design) |
|---|---|---|---|
| L. salivarius LS01 B. breve BR03 + maltodextrin | 1×109 CFU (of each) Not stated | Moderate/severe atopic dermatitis | 223(randomised double-blinded active treatment vs placebo study) |
| proBiotik® (B. bifidum, L. acidophilus, L. casei and L. salivarius) | 2×109 CFU (total) | Atopic dermatitis | 207(double-blind, randomised, placebo-controlled study) |
| L. pentosus b240 | 2×1010 CFU | Common cold | 224(randomised, double-blind, placebo-controlled study) |
| Yakult® (L. casei Shirota) | 6.5×109 CFU | Allergic rhinitis | 210(double-blind, placebo-controlled study) |
| L. paracasei-33 | 2×109 CFU | Allergic rhinitis | 216(randomised, double-blind, placebo-controlled study) |
| L. acidophilus L-92 | Not stated | Atopic dermatitis | 225(double-blind, randomised, clinical study) |